Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTGX POWR Grades
- PTGX scores best on the Value dimension, with a Value rank ahead of 49.98% of US stocks.
- PTGX's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
- PTGX's current lowest rank is in the Growth metric (where it is better than 4.41% of US stocks).
PTGX Stock Summary
- Of note is the ratio of Protagonist Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 7.68% of US stocks have a lower such ratio.
- With a price/sales ratio of 63.74, Protagonist Therapeutics Inc has a higher such ratio than 95.99% of stocks in our set.
- The volatility of Protagonist Therapeutics Inc's share price is greater than that of 90.3% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Protagonist Therapeutics Inc are XENE, NRIX, SGMO, ENTA, and ORMP.
- Visit PTGX's SEC page to see the company's official filings. To visit the company's web site, go to www.protagonist-inc.com.
PTGX Valuation Summary
- PTGX's price/earnings ratio is -28.3; this is 177.53% lower than that of the median Healthcare stock.
- Over the past 62 months, PTGX's price/sales ratio has gone NA NA.
- Over the past 62 months, PTGX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PTGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTGX | 2021-08-31 | 84.7 | 6.5 | -28.3 | -26.1 |
| PTGX | 2021-08-30 | 81.7 | 6.2 | -27.3 | -25.0 |
| PTGX | 2021-08-27 | 83.6 | 6.4 | -27.9 | -25.7 |
| PTGX | 2021-08-26 | 82.4 | 6.3 | -27.5 | -25.3 |
| PTGX | 2021-08-25 | 85.7 | 6.5 | -28.6 | -26.4 |
| PTGX | 2021-08-24 | 86.8 | 6.6 | -29.0 | -26.7 |
PTGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PTGX has a Quality Grade of D, ranking ahead of 12.65% of graded US stocks.
- PTGX's asset turnover comes in at 0.07 -- ranking 291st of 682 Pharmaceutical Products stocks.
- RGNX, MBIO, and MTEM are the stocks whose asset turnover ratios are most correlated with PTGX.
The table below shows PTGX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.070 | 1 | -0.571 |
| 2021-06-30 | 0.088 | 1 | -0.513 |
| 2021-03-31 | 0.117 | 1 | -0.538 |
| 2020-12-31 | 0.127 | 1 | -0.678 |
| 2020-09-30 | 0.140 | 1 | -0.800 |
| 2020-06-30 | 0.100 | 1 | -0.977 |
PTGX Price Target
For more insight on analysts targets of PTGX, see our PTGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $31.75 | Average Broker Recommendation | 1.44 (Moderate Buy) |
PTGX Stock Price Chart Interactive Chart >
PTGX Price/Volume Stats
| Current price | $31.95 | 52-week high | $50.54 |
| Prev. close | $32.57 | 52-week low | $12.80 |
| Day low | $31.06 | Volume | 154,257 |
| Day high | $33.63 | Avg. volume | 820,422 |
| 50-day MA | $28.95 | Dividend yield | N/A |
| 200-day MA | $34.91 | Market Cap | 1.52B |
Protagonist Therapeutics, Inc. (PTGX) Company Bio
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.
Latest PTGX News From Around the Web
Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary HemochromatosisProtagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition which causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting® of t |
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor ConferencesProtagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler. |
Protagonist Therapeutics Inc. (NASDAQ: PTGX) An Analysis Is What You NeedProtagonist Therapeutics Inc. (NASDAQ:PTGX) traded at $34.64 at close of the session on Monday, 11/08/21, made an upward move of 2.67% on its previous days price. Looking at the stock we see that its previous close was $33.74 and the beta (5Y monthly) reads 1.55 with the days price range being $33.79 $34.99. In Protagonist Therapeutics Inc. (NASDAQ: PTGX) An Analysis Is What You Need Read More » |
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lessened by Goldman Sachs Group Inc.Goldman Sachs Group Inc. decreased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 391,943 shares of the companys stock after selling 22,191 shares during the quarter. Goldman Sachs Group Inc. owned 0.82% of Protagonist [] |
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $56.75Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has earned an average recommendation of Buy from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that [] |
PTGX Price Returns
| 1-mo | 2.54% |
| 3-mo | -35.70% |
| 6-mo | -8.32% |
| 1-year | 32.24% |
| 3-year | 393.82% |
| 5-year | 31.70% |
| YTD | 58.48% |
| 2020 | 185.96% |
| 2019 | 4.75% |
| 2018 | -67.64% |
| 2017 | -5.41% |
| 2016 | N/A |
Loading social stream, please wait...